Answers are grounded in this paper and cite their sources.
Experiment shows tRNA modification improves translation efficiency of codon-rich mRNA, suggesting a novel vaccine strategy.
Although messenger RNA (mRNA) vaccines have been employed to prevent the spread of COVID-19, they are still limited by instability and low translation capacity. Alterations in tRNA abundance and modification, linking codon optimality, impact mRNA stability and protein output in a codon-dependent manner, suggesting tRNA as a potential translation enhancer. Here, we report a strategy named tRNA-plus to augment translation via artificially modulating tRNA availability. Overexpression of specific tRNAs enhances the stability and translation efficiency of SARS-CoV-2 Spike mRNA, boosting protein levels up to 4.7-fold. Additionally, chemically synthesized tRNAs bearing multiple site-specific modifications, particularly at the anticodon-loop and TΨC-loop, exhibit on average ~4-fold higher decoding efficacy than unmodified tRNAs, along with increased stability and reduced immunotoxicity. Furthermore, codelivery of Spike mRNA vaccine and tRNA through lipid nanoparticles elicits augmented humoral and cellular immune responses in vivo. These results presented here provide a general approach to elevate mRNA translation potency, with applications in diverse translation-based fields. The Covid-19 vaccinations showed the potential for mRNA vaccines; however, the technology still has low translation capacity. Here, the authors report on a method of improving mRNA stability and translation by overexpressing tRNAs significantly bosting protein production.
No takes yet. Share an insight, caveat, or question.
Dong et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: